Currently, 3 anti-SARS-CoV-2 monoclonal antibody products have received Emergency Use Authorizations from the Italian Medicines Agency (AIFA) for the treatment of mild to moderate COVID-19 in non hospitalized patients with laboratory-confirmed SARS-CoV-2 infection who are at high risk for progressing to severe disease and/or hospitalization (bamlanivimab plus etesevimab, sotrovimab, and casirivimab plus imdevimab). Differently from casirivimab/imdevimab and sotrovimab, the European Medicines Agency (EMA) has never recommended authorising the combination bamlanivimab/etesevimab for treating COVID-19. Moreover, the evidence on sotrovimab relies on the interim analysis results of an ongoing randomised placebo-controlled clinical trial [1], unlike the combinations bamlanivimab/etesevimab and casirivimab/imdevimab, whose results of the randomised placebo-controlled trials were published after having completed the enrolment [2,3]. The study aims at assessing the non-inferiority of bamlanivimab plus etesevimab and sotrovimab vs. casirivimab plus imdevimab on COVID-19 progression in patients aged at least 50 years at an early stage of the disease. The progression of COVID-19 disease (hospitalization, need for supplementary oxygen therapy at home, death) within 14 days of randomisation is the composite outcome variable on which the calculation of the sample size is based. Based on available data regarding the reduction in the number of hospitalisations and medical visits with the use of casirivimab plus imdevimab at an early-stage of COVID-19, a disease progression of 5% has been estimated in the reference arm. 5% delta margin was considered clinically relevant, taking into account both the estimates of disease progression in the study population in absence of early treatment with monoclonal antibodies (20%, based on national data) and the efficacy of the reference standard. Therefore, 1260 participants will be randomly assigned in an equal ratio between the reference standard and each of the other two experimental arms (1:1:1). Randomization will be computer-generated in permuted blocks with a stratification based on site.

开始日期2021-12-09

申办/合作机构

Azienda Ospedaliera Universitaria Integrata Verona

[+2]

NCT04796402 / Unknown status临床4期

A Pragmatic Eight Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19

The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.

开始日期2021-03-17

申办/合作机构

Fraser Health Authority

[+2]

NCT04790786 / Terminated临床4期IIT

The UPMC OPtimizing Treatment and Impact of Monocolonal antIbodieS Through Evaluation for COVID-19 Trial

Multiple monoclonal antibodies (mABs) have been shown to reduce viral burden and improve clinical outcomes, have been granted FDA Emergency Use Authorization (EUA) for use in select populations, and are routinely used in the UPMC Health System, which has made expanded access a priority. However, the comparative effectiveness of these mABS is unknown. The National Academies of Sciences, Engineering, and Medicine has called for expanded access and clinical use of mABs, noting it is "critical to collect data and evaluate whether they are working as predicted". This pragmatic evaluation will determine the relative effects of the EUA-governed mABs versus each other. When U.S. government mAB policies change (e.g., FDA grants or revokes EUAs), UPMC Health System policies and the evaluated mABs will accordingly change.

开始日期2021-03-10

申办/合作机构

University of Pittsburgh Medical Center

[+1]

100 项与巴尼韦单抗相关的临床结果

登录后查看更多信息

100 项与巴尼韦单抗相关的转化医学

登录后查看更多信息

100 项与巴尼韦单抗相关的专利（医药）

登录后查看更多信息

262

项与巴尼韦单抗相关的文献（医药）

2023-12-01·Computers in biology and medicine

Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies

Article

作者: Podgornik, Rudolf ; Ching, Wai-Yim ; Adhikari, Puja ; Jawad, Bahaa

The emergence of Omicron SARS-CoV-2 subvariants (BA.1, BA.2, BA.4, and BA.5), with an unprecedented number of mutations in their receptor-binding domain (RBD) of the spike-protein, has fueled a resurgence of COVID-19 infections, posing a major challenge to the efficacy of existing vaccines and monoclonal antibody (mAb) therapeutics. We conducted a systematic molecular dynamics (MD) simulation to investigate how the RBD mutations of these subvariants affect the interactions with broad mAbs including AstraZeneca (COV2-2196 and COV2-2130), Brii Biosciences (BRII-196), Celltrion (CT-P59), Eli Lilly (LY-CoV555 and LY-CoV016), Regeneron (REGN10933 and REGN10987), Vir Biotechnology (S309), and S2X259. Our results show a complete loss of binding for COV2-2196, BRII-196, CT-P59, and LY-CoV555 with all Omicron RBDs. Additionally, REGN10987 totally loses its binding with BA.1, but retains a partial binding with BA.2 and BA.4/5. The binding reduction is significant for LY-CoV016 and REGN10933 but moderate for COV2-2130. S309 and S2X259 retain their binding with BA.1 but exhibit decreased binding with other subvariants. We introduce a mutational escape map for each mAb to identify the key RBD sites and the corresponding critical mutations. Overall, our findings suggest that the majority of therapeutic mAbs have diminished or missing activity against Omicron subvariants, indicating the urgent need for a new therapeutic mAb with a better design.

2023-12-01·Journal, genetic engineering & biotechnology

Insights on the interaction of SARS-CoV-2 variant B.1.617.2 with antibody CR3022 and analysis of antibody resistance

Article

作者: Ks, Sandhya ; Nair, Achuthsankar S

Background:

The existence of mutated Delta (B.1.617.2) variants of SARS-CoV-2 causes rapid transmissibility, increase in virulence, and decrease in the effectiveness of public health. Majority of mutations are seen in the surface spike, and they are considered as antigenicity and immunogenicity of the virus. Hence, finding suitable cross antibody or natural antibody and understanding its biomolecular recognition for neutralizing surface spike are crucial for developing many clinically approved COVID-19 vaccines. Here, we aim to design SARS-CoV-2 variant and hence, to understand its mechanism, binding affinity and neutralization potential with several antibodies.

Results:

In this study, we modelled six feasible spike protein (S1) configurations for Delta SARS-CoV-2 (B.1.617.2) and identified the best structure to interact with human antibodies. Initially, the impact of mutations at the receptor-binding domain (RBD) of B.1.617.2 was tested, and it is found that all mutations increase the stability of proteins (ΔΔG) and decrease the entropies. An exceptional case is noted for the mutation of G614D variant for which the vibration entropy change is found to be within the range of 0.133–0.004 kcal/mol/K. Temperature-dependent free energy change values (ΔG) for wild type is found to be − 0.1 kcal/mol, whereas all other cases exhibit values within the range of − 5.1 to − 5.5 kcal/mol. Mutation on spike increases the interaction with the glycoprotein antibody CR3022 and the binding affinity (CLUSpro energy = − 99.7 kcal/mol). The docked Delta variant with the following antibodies, etesevimab, bebtelovimab, BD-368–2, imdevimab, bamlanivimab, and casirivimab, exhibit a substantially decreased docking score (− 61.7 to − 112.0 kcal/mol) and the disappearance of several hydrogen bond interactions.

Conclusion:

Characterization of antibody resistance for Delta variant with respect to the wild type gives understanding regarding why Delta variant endures the resistance boosted through several trademark vaccines. Several interactions with CR3022 have appeared compared to Wild for Delta variant, and hence, it is suggested that modification on the CR3022 antibody could further improve for the prevention of viral spread. Antibody resistance decreased significantly due to numerous hydrogen bond interactions which clearly indicate that these marketed/launched vaccines (etesevimab) will be effective for Delta variants.

Graphical Abstract:

2023-11-01·Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada

Randomized trial of the safety and efficacy of anti-SARS-CoV-2 mAb in the treatment of patients with nosocomial COVID-19 (CATCO-NOS).

Article

作者: Murthy, Srin ; Sligl, Wendy ; Somayaji, Ranjani ; O'Neil, Conar ; Tremblay, Alain ; Sonpar, Ashlesha ; Hoang, Holly ; Conly, John ; Fowler, Robert

Background:

Patients with nosocomial acquisition of COVID-19 have poor outcomes but have not been included in therapeutic trials to date.

Methods:

A pragmatic open-label randomized controlled trial of anti-SARS-CoV-2 monoclonal antibodies (mAb) was performed in hospitalized patients with nosocomial COVID-19 infection in acute care hospitals spanning a provincial health care network. Participants within 5 days of first positive test or symptom onset were randomized to standard of care (SOC) plus a single dose intravenous mAb treatment (bamlanivimab or casirivimab/imdevimab) or SOC alone on a 2:1 basis. The primary study endpoint was the need for invasive mechanical ventilation (IMV) or inpatient mortality by day 60 after randomization.

Results:

Forty-six participants were enrolled from 13 hospitals between February 14 and October 8, 2021: 31 in the mAb and 15 in the SOC arm. IMV or inpatient mortality up to day 60 occurred in 4 (12.9%) participants in the mAb versus 3 in the SOC arm (20.0%), difference of -7.1% (95% CI -22.5 to 13.4, p = 0.67). The study was terminated early due to lack of equipoise as effectiveness of anti-viral therapies and mAb was published in similar high-risk patient populations.

Conclusions:

The trial was underpowered to detect meaningful differences given its early termination. The study does highlight the feasibility of undertaking trials in this patient population using a pragmatic approach allowing for trial participation and treatment access across a large health care network and may serve as a template for future designs.

232

项与巴尼韦单抗相关的新闻（医药）

2024-01-23

·Pharma Manufacturing

Eli Lilly under fire for manufacturing issues at NJ plant

Recent inspections by the FDA at Eli Lilly's Branchburg, New Jersey plant have revealed significant manufacturing problems, reported Reuters . The FDA identified eight deficiencies, including challenges in tracking the manufacturing process, lapses in quality controls, calibration issues, and inadequate facility maintenance during a July inspection. The inspection report, obtained by Reuters through a Freedom of Information Act request, highlighted concerns about the protection of electronic records, insufficient staff training for drug testing, and neglect of equipment, raising potential risks of data manipulation and contamination. In a statement to Reuters, Eli Lilly said it responded to the inspection by seeking FDA approval for "additional flexibility" to produce the migraine treatment Emgality on a different line. While the company said that most issues were addressed during the inspection, experts, including former FDA official Steven Lynn, expressed serious concerns about the recurring problems at the Branchburg facility. The FDA declined to comment on the specific issues, but the manufacturing lapses could be categorized as "Official Action Indicated." The severity of the FDA's response will depend on the company's corrective actions to ensure drug quality. In 2021, the U.S. Department of Justice delved into quality concerns surrounding the same Eli Lilly plant in New Jersey, responsible for manufacturing the COVID-19 treatment, bamlanivimab. Reuters had reported employee allegations that an executive at the facility had destroyed FDA-required documents to conceal severe quality lapses. This incident marked a recurring problem, as a former human resources officer accused the company earlier in the year of destroying or falsifying documents related to quality issues. A previous FDA inspection in 2019 at the plant uncovered various quality problems, including inadequate investigations into issues tied to the production of the company’s Trulicity drug, resulting in an Official Action Indicated. Responding to these challenges, the company enlisted an independent consultant to address compliance issues at the facility.

2023-12-26

·生物制品圈

高峰/高福合作发现新的可中和奥密克戎抗体

目前，针对SARS - CoV - 2 S蛋白受体结合域( receptor binding domain，RBD )的单克隆抗体根据其结合表位分为7类。然而，这些抗体大多受到SARS - CoV - 2 Omicrom及其亚变种的严重损害，尤其是最近的BQ.1 . 1、XBB及其衍生物。鉴定针对目前流行的变异体的广谱中和MAbs是必要的。2023年12月18日，中国科学院天津工业生物技术研究所高峰及中国科学院微生物研究所高福共同通讯在PNAS 上在线发表题为“Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2”的研究论文，该研究在S蛋白中发现了一个"呼吸"的隐秘表位，将其命名为RBD-8。该研究分离到2株识别该抗原表位的人源单克隆抗体BIOLS56和IMCAS74，它们对SARS - CoV、穿山甲来源的冠状病毒以及所有检测到的SARS - CoV - 2变异株均具有广泛的中和能力。BIOLS56通过制备双特异性MAb来中和BQ.1和BQ.1 . 1，从而拯救出免疫逃逸抗体RBD - 5 MAb IMCAS-L4.65，从而制备出能够覆盖目前所有流通的O μm亚变异体的MAb。结构分析表明，RBD - 8抗体的中和作用取决于表位暴露的程度，而表位暴露的程度受抗体结合角度和血管紧张素转化酶2结合诱导的上调RBD数量的影响。这种识别非受体结合基序( non-receptor binding motif，non-RBM )的隐匿性表位为COVID - 19通用治疗性抗体和疫苗的研发提供了指导。自2020年3月世界卫生组织( WHO的)宣布大流行以来，2019冠状病毒病( COVID-19 )大流行已持续3年，仍对全球构成威胁。严重急性呼吸综合征冠状病毒2 (severe acute respiratory syndrome coronavirus 2( SARS-CoV-2 ))，COVID-19 )与SARS - CoV同属于冠状病毒科β冠状病毒属，引起两种严重的人类疾病。SARS - CoV - 2病毒粒子主要由基因组核酸和蛋白质组成，即刺突( S )、膜( M )、囊膜( E )和核衣壳( N )蛋白，其中S、M和E蛋白镶嵌在病毒囊膜中，N蛋白保护病毒基因组。值得注意的是，编码S蛋白的基因是各种变异的重要突变热点。尽管已有多种治疗性抗体和疫苗应用于临床，但由于SARS - CoV - 2变异株的不断出现，特别是VOCs ( variant of concern )的不断出现，使得这些治疗方法的疗效大打折扣，防疫工作仍然面临着巨大的挑战。因此，迫切需要开发广谱的保护性抗体和通用型疫苗。SARS - CoV和SARS - CoV - 2均通过其S蛋白识别血管紧张素转换酶2 ( ACE2 )介导病毒进入。S蛋白主要由S1和S2两个亚结构域组成，其中S1含有负责识别ACE2进入宿主细胞的受体结合结构域( receptor binding domain，RBD )。因此，阻断RBD与ACE2的结合是中和抗体研究的重点。然而，随着VOCs的出现，这些中和抗体的疗效往往被大大削弱甚至消融，其中包括以抗体为基础的药物etesevimab (又名CB6)、REGN10933和LY - CoV555。另一方面，由于SARS - CoV - 2的RBD与SARS - CoV具有75 %的序列一致性，也有一些针对SARS - CoV - 2和SARS - CoV的RBD的交叉中和抗体的研究，以S309 为代表。同样，S309对变体的中和能力也受到了明显的削弱，尤其是对VOCs的中和能力。BIOLS56和IMCAS74被定义为RBD-8类抗体（图源自PNAS ）Hastie等利用基于表面等离子共振( surface plasmon resonance，SPR )的竞争实验，将冠状病毒免疫治疗联盟中针对SARS - CoV - 2 RBD的抗体分为RBD - 1、RBD - 2、RBD - 3、RBD - 4、RBD - 5、RBD - 6和RBD - 7七类。RBD - 1、RBD - 2和RBD - 3类抗体以不同的角度与RBD的受体结合基序结合，而" up "的RBD构象是结合所必需的。当RBD处于"上"或"下"状态时，RBD - 4和RBD - 5类抗体结合在RBD外表面的不同位置。对于RBD - 6和RBD - 7类抗体，它们都与RBD的内表面结合，而RBD的内表面通常被称为隐秘表位，两个" up "的RBD是必需的。基于此，该研究报道了两株针对一个隐匿表位的人源单克隆抗体( hMAbs ) BIOLS56和IMCAS74，并将其命名为RBD - 8。重要的是，该隐秘表位包含了沙粒病毒间的保守残基。因此，靶向RBD - 8的抗体具有广谱中和杆状病毒的能力。虽然BIOLS56的中和作用较弱，但它拯救了免疫逃逸抗体IMCAS - L4.65以中和BQ.1和BQ.1 . 1，扩大了双特异性抗体以中和所有已知的待测VOCs。文献检索显示，许多RBD - 8 MAb已被不同的研究组发现，但尚未被正式命名为新的研究组。此外，该研究提供了一个模型，通过结构分析来解释为什么不同的RBD - 8抗体对sarbecoviruses表现出不同程度的中和作用。这些发现表明，暴露的隐匿性表位RBD - 8是开发通用疫苗和抗体的一个有前途的靶点。利用该表位设计的双特异性抗体，结合其他表位，是避免病毒逃逸的良好候选者。参考信息：https://doi-org.libproxy1.nus.edu.sg/10.1073/pnas.2314193120识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场

疫苗临床结果临床研究

2023-08-15

·Pharmaceutical Technology

Signal: UnitedHealth’s Amedisys acquisition under further DOJ scrutiny

Isaac Hanson The study plans to enrol up to 500,000 subjects of which at least 5,000 are expected to get bamlanivimab therapy. Credit: Willfried Wende from Pixabay. On 11 August it was announced that the proposed acquisition of home and personal care company Amedisys by healthcare giant UnitedHealth Group would be paused after the Department of Justice (DOJ) requested further information from the companies. The deal, announced in late June, valued Amedisys at $101 a share, a roughly 10% premium on its closing price at the time of the agreement. It is one of a spate of acquisitions by UnitedHealth, which has been making moves into the home health market for some time. Recommended Reports Reports Post-Transplant Lymphoproliferative Disorder Drugs in Development by Stages, Target, MoA, RoA, Mo... GlobalData Reports LOA and PTSR Model - Venetoclax in Rhabdomyosarcoma GlobalData View all Companies Intelligence UnitedHealth Group Inc Amedisys Inc LHC Group Inc Change Healthcare LLC Optum Inc View all In February, the company acquired LHC Group , another player in the field, for $5.4bn. This deal also faced scrutiny from regulators. The Federal Trade Commission (FTC) requested more information last June, extending the timeline of the deal by around six months but ultimately allowing it to happen. The home health market is an increasingly lucrative one. As populations across the US, and the rest of the world, age, the demand for low cost, accessible care will only increase. As such, large insurers and providers are rushing to get a cut of the profits, often through pricey acquisitions. Companies like UnitedHealth are asset rich – with its total current assets sitting at over $89bn – and it is looking at throwing the weight of that cash at smaller firms in order to increase their portfolio. Last year it was finally able to buy healthtech company Change Healthcare for $13bn in a full cash deal, a 41.2% premium on the closing price of Change shares when the deal was announced the year before . These levels of premiums are necessary both to fight off competition – UnitedHealth jumped in with an offer for Amedisys after it had agreed to be bought by Optum just a month before – and because the companies being bought are highly successful in their own right. With giants able to pay over the odds for market share in new sectors of the industry, the only way to prevent their expansion is regulatory oversight. The fear of the DOJ is that the rapid pace of mergers and acquisitions being carried out by the company will create anti-competitive conditions in the home health market, despite LHC and Amedisys having very little geographical overlap. This is indicative of the more active role regulators have taken in the healthcare market since President Biden’s executive order in 2021 ordering more vigorous oversight. Likely encouraged by this, the FTC and DOJ have proposed updated antitrust guidelines that experts argue will make healthcare M&A more difficult, particularly in the case of deals like this where the acquirer isn’t currently a major player in the acquisition space. UnitedHealth reported a 16% year-on-year earnings growth in Q2 of this year, raising revenue to $92.9bn. Our signals coverage is powered by GlobalData’s Disruptor data , which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors. These signals help us to uncover key innovation areas in the sector and the themes that drive them. They tell us about the topics on the minds of business leaders and investors and indicate where leading companies are focusing their investment, deal-making and R&D efforts.

并购

100 项与巴尼韦单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11936	-	D06BB	DB15718

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒感染	美国	Eli Lilly & Co.	2021-02-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05780268 (CTgov)	临床3期	新型冠状病毒感染	314	LY3819253+Remdesivir (LY3819253 Plus SOC)	繭廠憲鑰醖廠網簾膚願(顧糧憲廠廠網築顧夢選) = 鏇糧衊壓顧壓獵鹹遞艱糧繭範壓衊鬱淵淵夢壓 (齋願蓋蓋齋襯鏇鏇鹽蓋, 艱艱鬱窪襯憲網廠鏇淵 ~ 繭製簾顧範醖襯膚齋遞) 更多	-	2023-10-10
				Placebo+Remdesivir (Placebo Plus SOC)	繭廠憲鑰醖廠網簾膚願(顧糧憲廠廠網築顧夢選) = 顧廠鬱壓糧遞積窪憲鬱糧繭範壓衊鬱淵淵夢壓 (齋願蓋蓋齋襯鏇鏇鹽蓋, 鏇築鏇簾簾選鏇廠網築 ~ 鑰範顧觸鏇範顧淵觸糧) 更多
NCT04427501 (BLAZE-1, Pubmed \| Open Forum Infect Dis)	临床3期	新型冠状病毒感染	769	Bamlanivimab and Etesevimab	淵艱蓋鑰膚夢衊願壓衊(衊膚鬱鹽構鏇製構積選) = 襯壓構鏇繭窪窪觸糧鏇膚鬱願鹽醖醖繭壓鹽繭 (蓋簾觸憲鑰鹽襯築鬱繭 )	积极	2022-05-01
				Placebo	淵艱蓋鑰膚夢衊願壓衊(衊膚鬱鹽構鏇製構積選) = 顧鏇鏇夢窪選選鹽淵淵膚鬱願鹽醖醖繭壓鹽繭 (蓋簾觸憲鑰鹽襯築鬱繭 )
NCT04656691 (CTgov)	临床4期	新型冠状病毒感染	139	Bamlanivimab	選憲遞範選壓製壓築廠(齋餘築廠廠醖網衊蓋製) = 簾糧廠遞壓範膚鏇繭鏇齋網壓蓋窪鏇鏇獵選鹹 (願觸觸艱廠鏇遞簾願淵, 窪餘觸觸簾繭鏇製糧鹹 ~ 選構窪憲憲餘積觸夢製) 更多	-	2022-03-18
NCT04497987 (CTgov)	临床3期	新型冠状病毒感染	1,180	Placebo (Placebo)	顧襯範繭觸壓遞憲觸鏇(襯鹹壓壓簾構獵淵積製) = 壓艱鏇艱餘艱築獵醖膚鏇鹹製獵鑰顧艱窪淵糧 (襯網夢鹹觸顧膚鑰鏇壓, 鬱構遞鑰壓襯鏇簾顧鑰 ~ 網鹹衊鑰鑰膚壓遞膚繭) 更多	-	2022-02-04
				Bamlanivimab (4200mg Bamlanivimab)	顧襯範繭觸壓遞憲觸鏇(襯鹹壓壓簾構獵淵積製) = 膚糧衊廠蓋鏇遞夢齋積鏇鹹製獵鑰顧艱窪淵糧 (襯網夢鹹觸顧膚鑰鏇壓, 構獵艱齋憲襯憲齋糧壓 ~ 網製淵艱鹹壓醖夢顧繭) 更多
NCT04518410 (ACTIV-2/A5401, Pubmed)	临床2期	新型冠状病毒感染	317	Bamlanivimab 7000 mg	(繭製壓夢廠糧餘繭鏇衊) = 鏇鹽鹹構遞積獵蓋構廠糧顧繭餘願範憲繭鏇觸 (構積顧醖遞構淵糧網範 )	-	2021-12-21
				Bamlanivimab 700 mg	(繭製壓夢廠糧餘繭鏇衊) = 窪齋襯鬱顧獵選醖齋選糧顧繭餘願範憲繭鏇觸 (構積顧醖遞構淵糧網範 )
NCT04537910 (CTgov)	临床1期	-	25	LY3819253 (150 mg LY3819253 SC)	鑰簾艱網構憲壓製糧選(鏇鑰糧獵衊膚構範顧廠) = 夢衊鏇繭醖範願網醖遞鬱簾廠廠築製獵衊齋遞 (襯齋鏇鬱選繭簾選鹹夢, 廠築壓獵鹽衊壓夢齋餘 ~ 選築鹹鬱壓壓鹽鑰蓋鹹) 更多	-	2021-12-06
				LY3819253 (350 mg LY3819253 SC)	鑰簾艱網構憲壓製糧選(鏇鑰糧獵衊膚構範顧廠) = 夢繭齋鹽構鏇壓憲廠製鬱簾廠廠築製獵衊齋遞 (襯齋鏇鬱選繭簾選鹹夢, 餘憲選醖築製鬱窪築鏇 ~ 觸糧選艱蓋鏇簾膚構壓) 更多
NCT04701658 (CTgov)	临床2期	新型冠状病毒感染	109	Bamlanivimab	齋鏇遞餘製衊蓋壓獵觸(繭淵窪獵襯淵壓範範艱) = 願鏇夢夢網醖鏇廠築積艱壓築憲淵艱窪簾壓獵 (夢膚築積獵鹹選築膚繭, 醖鬱膚鑰鹽觸襯積鏇構 ~ 鹹淵網艱窪選鹹遞網鹹) 更多	-	2021-11-16
NCT04411628 (CTgov)	临床1期	新型冠状病毒感染	26	Placebo	願製遞願繭積選齋醖壓(廠餘衊窪願窪簾蓋簾醖) = 艱網齋膚網鏇鬱願壓積憲廠齋遞憲餘選遞蓋齋 (廠憲觸蓋範鬱簾獵襯獵, 艱鏇築積鬱壓衊餘鹹鏇 ~ 壓顧鏇遞選遞襯觸衊鬱) 更多	-	2021-11-09
NCT04427501 (BLAZE-1, Pubmed \| Br Dent J) 人工标引	临床2/3期	新型冠状病毒感染	1,035	bamlanivimab+etesevimab	憲選觸憲觸蓋繭糧顧糧(簾鏇糧膚願餘觸簾繭製) = 顧範糧窪繭壓構鑰鑰簾艱淵築窪網繭鑰獵淵襯 (膚膚願蓋網願觸醖窪艱 ) 更多	积极	2021-10-07
				Placebo	憲選觸憲觸蓋繭糧顧糧(簾鏇糧膚願餘觸簾繭製) = 齋廠鑰膚蓋鬱觸糧餘繭艱淵築窪網繭鑰獵淵襯 (膚膚願蓋網願觸醖窪艱 ) 更多
NCT04497987 (Pubmed) 人工标引	临床4期	新型冠状病毒感染	1,175	Bamlanivimab	積繭網憲積廠構蓋廠鏇(範構鹽鬱築獵醖廠醖鑰) = 簾鹹簾範選淵製醖鏇廠鬱醖鑰蓋憲鹽鑰餘夢築 (製鹽製積夢醖選範襯襯 ) 更多	积极	2021-07-06
				Placebo	積繭網憲積廠構蓋廠鏇(範構鹽鬱築獵醖廠醖鑰) = 築鏇遞鑰鑰襯醖廠遞憲鬱醖鑰蓋憲鹽鑰餘夢築 (製鹽製積夢醖選範襯襯 ) 更多